mHSPC VL

Treatment Intensification in Metastatic Castrate-Sensitive Prostate Cancer - Zachary Klaassen

Details
In this discussion, Christopher Wallis discusses treatment intensification in metastatic castrate-sensitive prostate cancer (mCSPC). Dr. Klaassen and Dr. Wallis focus their discussion on several studies in the United States and across the globe that have looked at the real-world utilization of androgen deprivation therapy (ADT) plus other agents in the mCSPC disease space. Drs. Klaassen and Wallis...

Considerations for Integrating Triplet Therapy Into Clinical Practice - Evan Yu

Details
Alicia Morgans is joined in conversation by Evan Yu to discuss the integration of triplet therapy into clinical practice for metastatic prostate cancer patients focusing on the patient population for this therapy. The conversation also includes discussing chemo-fit patients and the presentation of chemotherapy and triplet therapy as a standard for patients to refuse, emphasizing the need for activ...

Meta-Analysis Sheds Light on Optimal Treatment Strategies for Metastatic Hormone-Sensitive Prostate Cancer - Benjamin Maughan

Details
Alicia Morgans interviews Ben Maughan focusing on a published network meta-analysis involving 11 randomized control trials for patients treated for metastatic hormone-sensitive prostate cancer. The analysis stirred significant debate on Twitter and sought to establish whether triplet therapy was superior to other approaches like ADT plus docetaxel and ADT plus an AR-targeted therapy. Dr. Maughan e...

Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg

Details
In this video, Alicia Morgans speaks with Cora Sternberg about the evolution of prostate cancer care over the last 20 years, highlighting recent advances and current barriers. Prostate cancer research includes advancements in novel hormonal therapies such as androgen deprivation therapy with a novel hormonal therapy or docetaxel improving overall survival in its metastatic hormone-sensitive stage....

Progress in Treating Metastatic Castration-Sensitive Prostate Cancer - Karim Fizazi

Details
Karim Fizazi discusses the substantial progress made in treating metastatic castration-sensitive prostate cancer. In their conversation, Dr. Fizazi emphasizes the importance of understanding different patient scenarios based on volume and the timing of the metastasis, highlighting the distinctions between de novo metastatic disease and relapse after local treatment. He breaks down four scenarios t...

mCSPC Couplet vs Triplet Therapy LUGPA 2022 Presentation - Alicia Morgans

Details
At the 2022 Large Urology Group Practice Association (LUGPA) annual meeting, Alicia Morgans presented on couplet versus triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Biography: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Related Content: APCCC 2022: Treatment...

Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay

Details
Rana McKay and Alicia Morgans discuss the CYCLONE 3 trial in progress in high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Recent data from the ARASENS trial shows a survival benefit for treatment intensification with ADT + docetaxel + a novel hormonal agent, triplet therapy, vs ADT + docetaxel in selected patients. Yet, there is a significant medical need to expand therapeutic optio...

The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz

Details
Russell Szmulewitz joins Charles Ryan in a discussion highlighting three abstracts in the metastatic hormone-sensitive prostate cancer treatment landscape when discussing treatment intensification. In highlighting these studies outlines the following 5 key questions for the field of mHSPC: Do all patients with mHSPC benefit from ADT intensification? When should we use triplet (ADT + ARSI + docetax...

8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam

Details
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable level...

The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore

Details
Alicia Morgans is joined by Neal Shore, who provides his perspective on the phase 3 ARASENS data for patients with metastatic hormone-sensitive prostate cancer, which demonstrates the superiority in terms of survival and numerous other secondary endpoints of triplet versus doublet therapy. In ARASENS, darolutamide + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death...